Maxim Group Reiterates Bullish View on Opexa Therapeutics (OPXA)

Maxim Group analyst Jason Kolbert reiterated a Buy rating and $18 price target on Opexa Therapeutics (NASDAQ: OPXA) mid-day.

The analyst highlighted:

• Opexa recently hosted an R&D event in NYC (November 10, 2015) with KOLs Dr. Clyde Markowitz and Dr. Ben Greenberg, whose expertise in both MS and Opexa's second indication, neuromyelitis optica (NMO), an unmet medical need, were discussed. Key topics were brain atrophy as an endpoint in MS and NMO attacks.
• We present the following paper on brain atrophy as a viable endpoint in MS (see details section below).
• The Tcelna phase IIb study in SPMS (secondary progressive multiple sclerosis) is now fully enrolled and 92% of patients have completed their follow-up visits. Top-line data (brain atrophy via MRI) is expected in 2H16. If positive, it should trigger Merck Serono (MKGAY-$33.26-NR) to opt in and take the reins for a pivotal phase III study (which the companies are currently discussing).

For an analyst ratings summary and ratings history on Opexa Therapeutics click here. For more ratings news on Opexa Therapeutics click here.

Shares of Opexa Therapeutics closed at $3.87 yesterday.

You May Also Be Interested In

• Truist Securities Downgrades Procept BioRobotics Corp (PRCT) to Hold
• Abivax (ABVX) PT Raised to $155 at Truist Securities
• General Mills (GIS) PT Raised to $32 at TD Cowen